A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Arlington Scientific Broadens Product Portfolio and Further Expands its Product Offering Through the acquisition of Non-Mammalian Blocking Buffers

Arlington Scientific, Inc. (ASI) is pleased to announce that it has acquired the non-mammalian blocking buffer product line from Clark McDermith, former owner of EastCoast Bio. Arlington Scientific will now be the exclusive worldwide manufacturer of these proprietary blocking buffers for markets including In-Vitro Diagnostic (IVD) manufacturers and for research and development institutions.

“This acquisition will provide strategic value to Arlington Scientific in the form of new product markets, expansion of its manufacturing capabilities, increased sales and new customers. This is in line with ASI’s strategy of being a progressive industry leader through the pursuit of quality products, superior customer service, high corporate values, and a genuine appreciation for each customer,” said David Porter, Chief Business Development officer for Arlington Scientific.

ASI is an FDA registered establishment with over 36 years of medical device manufacturing expertise in diagnostic reagents and serological test kits. ASI is at the forefront of innovation and was the first to develop an automated nontreponemal algorithm for the detection of syphilis; the first to develop the only automated nontreponemal (RPR) syphilis analyzer FDA cleared for diagnostic, blood donor screening and cadaveric (non-heartbeating) donor screening; the first to include mercury free RPR reagents, implementation of liquid controls, screw cap lids, warp resistant test cards, extended shelf life for reagents and developing in-vitro diagnostic RPR tests for use with CPD and CPDA-1 anticoagulants.

Product Overview:

Balance Blocking Buffer (ELISA/WB/Lateral Flow)Universal blocking reagent provides superior blocking in sensitive assay systems (Available in three formulations, with PBS, PBS with a surfactant or with Tris).
Aquatic Block Serum FreeFormerly called SeaBlock Serum Free (Lateral Flow/ELISA)Serum and plasma-free optimized for use with nitrocellulose in lateral flow assays and ELISA systems (Available in two formulations, with PBS or Tris).
Aquatic BlockFormerly called SeaBlock(ELISA/EIA/WB)Formulated for ELISA assay development. Can be diluted to 1:1 to 1:50 to reduce signal-to-noise ratio (Available in two formulations, with PBS or Tris).
AquaBlock (WB/EIA/Chemiluminescence)Significantly reduces non-specific protein attachment when used with a blotting membrane.
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Sachita Shah, Sr. Director, Global Health, Butterfly Network, "Butterfly is proud to continue improving maternal health equity through Phase Two of the largest-scale handheld ultrasound distribution and training ever conducted in Sub-Saharan Africa. South Africa is an emerging market that continues to have disproportionately high rates of maternal mortality and stillbirth. Patients need easier access to antenatal imaging, and clinicians need better capabilities for screening high-risk conditions that lead to disproportionately worse pregnancy outcomes in rural areas in the public sector. Together with CHAI and GUSI, we can tackle this by making ultrasound much more accessible, so high-risk conditions can be identified earlier in care, which is known to improve outcomes.”
The clinical Study will enroll up to 97 patients at up to 12 European investigational sites. Completion of the study is expected this year, and results will support CE mark and pre-market approval submissions reports Vivasure Medical.
Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.

By using this website you agree to accept Medical Device News Magazine Privacy Policy